Transforming the Drug Discovery Paradigm for Heart Disease
Current Paradigm vs. Valo Paradigm
Valo’s in vitro human biology fills the human translation gap: A significant translation gap exists between human cardiac physiology and the existing in vitro biochemical assays and animal models designed to replicate it. As such, the ability of these commonly used cardiac models to predict clinical data is limited. Valo engineers the highest fidelity human cardiac biology with translational relevance to humans in an in vitro setting. This technology reduces dependence on expensive, time-consuming animal studies and accelerates cycles in the drug discovery and development process.

Generation of Cardiotype tissues on the Valo Platform

Cardiotype™ tissues exhibit unprecedented human cardiac physiology

Cardiac Tissue Models & Measurements
We recognize that drug development is a dynamic process, so we leverage the flexibility of our platform to create custom study plans, empowering our partners to ask complex questions about human response. At study onset, a cardiac tissue model is selected and Valo works with the partner to design an experiment to best interrogate those tissues. For long-term experiments, non-invasive contractility measurements can be collected over time in addition to conditioned media. At study completion, multiple endpoint measurements can be performed.

Valo’s integrated cardiac platform is enabling cardiovascular disease drug discovery and development
Human-based platform for validation of novel targets Using Valo biology, target validation is faster relative to traditional cardiac animal models (e.g. dogs, pigs)

Human-based platform for CV disease modeling incorporating human biology into early efficacy studies of disease increases the probability of success

Human-based phenotypic platform for compound optimization: Valo biology enables rapid cycle times and requires as little as 1 mg of compound

Cardiac risk assessment in a human-based model: Incorporating complex human biology into pre-clinical safety screens helps to stop unsafe drugs from entering the clinic and mitigates the use of animals.

Defined patient segments leveraging iPSC technology: Valo biology enables better informed clinical study design leading to smaller and more cost-effective clinical trials.

Valo data describes nuanced human physiology
